The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
Open accessAbstract
Purpose: To develop guidelines for performing and interpreting positron emission tomography (PET) imaging for treatment assessment in patients with lymphoma both in clinical practice and in clinical trials. Methods: An International Harmonization Project (IHP) was convened to discuss standardization of clinical trial parameters in lymphoma. An imaging subcommittee developed consensus recommendations based on published PET literature and the collective expertise of its members in the use of PET in lymphoma. Only recommendations subsequently endorsed by all IHP subcommittees were adopted. Recommendations: PET after completion of therapy should be performed at least 3 weeks, and preferably at 6 to 8 weeks, after chemotherapy or chemoimmunotherapy, and 8 to 12 weeks after radiation or chemoradiotherapy. Visual assessment alone is adequate for interpreting PET findings as positive or negative when assessing response after completion of therapy. Mediastinal blood pool activity is recommended as the reference background activity to define PET positivity for a residual mass ≥ 2 cm in greatest transverse diameter, regardless of its location. A smaller residual mass or a normal sized lymph node (ie, ≤ 1 × 1 cm in diameter) should be considered positive if its activity is above that of the surrounding background. Specific criteria for defining PET positivity in the liver, spleen, lung, and bone marrow are also proposed. Use of attenuation-corrected PET is strongly encouraged. Use of PET for treatment monitoring during a course of therapy should only be done in a clinical trial or as part of a prospective registry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationOllinger, J. M., & Fessler, J. A. (1997) · IEEE Signal Processing Magazine · doi:10.1109/79.560323 · Cited by 1,167
Positron-Emission Tomography and Assessment of Cancer Therapy
Juweid, M. E., & Cheson, B. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050276 · Cited by 750
Self-citationHutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.-M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2252 · Cited by 726
Shankar, L. K., Hoffman, J. M., Bacharach, S. L., Graham, M. M., Karp, J. S., Lammertsma, A. A., Larson, S. M., Mankoff, D. A., Siegel, B. A., den Abbeele, A. V., et al. (2006) · PubMed · Cited by 674
Self-citationProcedure guideline for tumor imaging with F-18 FDG PET/CT
Delbeke, D., Coleman, R. E., Guiberteau, M. J., Brown, M. L., Royal, H. D., Siegel, B. A., Townsend, D. W., Berland, L. L., Parker, J. A., Hübner, K. F., et al. (2006) · Cited by 620
Self-citationJerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999) · Blood · doi:10.1182/blood.v94.2.429 · Cited by 565
Schöder, H., Noy, A., Gönen, M., Weng, L., Green, D., Erdi, Y. E., Larson, S. M., & Yeung, H. W. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.072 · Cited by 491
Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., Vanuytsel, L., Bormans, G., Balzarini, J., De Wolf-Peeters, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.414 · Cited by 465
Self-citationUtility of FDG-PET scanning in lymphoma by WHO classification
Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J.-A., Zhuang, H., Pitsilos, S., Bagg, A., Downs, L., Mehrotra, A., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2778 · Cited by 437
Juweid, M. E., Wiseman, G. A., Vose, J. M., Ritchie, J. M., Menda, Y., Wooldridge, J. E., Mottaghy, F. M., Rohren, E. M., Blumstein, N. M., Stolpen, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.891 · Cited by 387
Self-citationSchaefer, N. G., Hany, T. F., Taverna, C., Seifert, B., Stumpe, K. D. M., von Schulthess, G., & Goerres, G. W. (2004) · Radiology · doi:10.1148/radiol.2323030985 · Cited by 344
Römer, W., Hanauske, A.-R., Ziegler, S. I., Thödtmann, R., Weber, W., Fuchs, C., Enne, W., Herz, M., Nerl, C., Garbrecht, M., et al. (1998) · PubMed · doi:10.1182/blood.v91.12.4464 · Cited by 335
Self-citationJerusalem, G., Beguin, Y., Najjar, F., Hustinx, R., Fassotte, M. F., Rigo, P., & Fillet, G. (2001) · Annals of Oncology · doi:10.1023/a:1011169332265 · Cited by 268
FDG-PET/CT in re-staging of patients with lymphoma
Freudenberg, L. S., Antoch, G., Sch�tt, P., Beyer, T., Jentzen, W., M�ller, S. P., G�rges, R., Nowrousian, M. R., Bockisch, A., & Debatin, J. F. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1375-y · Cited by 246
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT.
Antoch, G., Freudenberg, L. S., Beyer, T., Bockisch, A., & Debatin, J. F. (2004) · PubMed · Cited by 236
Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Maertens, J., Bormans, G., Thomas, J., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3842 · Cited by 226
Self-citationResidual mass in lymphoma may not be residual disease.
Canellos, G. P. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.6.931 · Cited by 220
Naumann, R., Vaic, A., Beuthien‐Baumann, B., Bredow, J., Kropp, J., Kittner, T., Franke, W., & Ehninger, G. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03147.x · Cited by 212
Self-citationJerusalem, G., Beguin, Y. P., Fassotte, M., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (2000) · PubMed · Cited by 203
Spaepen, K., Stroobants, S., Dupont, P., Bormans, G., Balzarini, J., Verhoef, G., Mortelmans, L., Vandenberghe, P., & Wolf-Peeters, C. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1120-6 · Cited by 195
Self-citationHoffmann, M., Kletter, K., Diemling, M., Becherer, A., Pfeffel, F., Petkov, V., Chott, A., & Raderer, M. (1999) · Annals of Oncology · doi:10.1023/a:1008312726163 · Cited by 165
de Wit, M., Bumann, D., Beyer, W., Herbst, K., Clausen, M., & Hossfeld, D. K. (1997) · Annals of Oncology · doi:10.1093/annonc/8.suppl_1.s57 · Cited by 164
Allen-Auerbach, M., Quon, A., Weber, W., Obrzut, S. L., Crawford, T. L., Silverman, D. H. S., Ratib, O. M., Phelps, M. E., & Czernin, J. G. (2004) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2004.08.004 · Cited by 116
Self-citationRole of Positron Emission Tomography in Lymphoma
Juweid, M. E., & Cheson, B. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.904 · Cited by 115
Self-citationSugawara, Y., Zasadny, K. R., Kison, P. V., Baker, L. H., & Wahl, R. L. (1999) · PubMed · Cited by 94
Weng, L., Noy, A., YEUNG, H. W. D., et al. (2005) · Cited by 94
Fabry, U., Neuerburg, J., Zimny, M., Bares, R., Osieka, R., Büll, U., & Cremerius, U. (2001) · Nuklearmedizin - NuclearMedicine · doi:10.1055/s-0038-1623988 · Cited by 49
Spaepen, K., Stroobants, S. G., Dupont, P. J., Vanderberghe, P., Thomas, J., de Groot, T., Balzarini, J. M., Wolf‐Peeters, C. D., Mortelmans, L. A., & Verhoef, G. E. G. (2001) · Digital Access to Libraries · Cited by 4
Self-citation
Cited by
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Self-citationRevised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Self-citationFrom RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
“Progression in the lungs, particularly in the presence of potential inflammation or infection while a patient is on treatment, should be viewed with great caution, as discussed in the revised response criteria in lymphoma (32,33).”
BackgroundInfluentialFDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Boellaard, R., Delgado-Bolton, R., Oyen, W. J. G., Giammarile, F., Tatsch, K., Eschner, W., Verzijlbergen, F. J., Barrington, S. F., Pike, L. C., Weber, W. A., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2961-x · Cited by 3,303
“Some criteria have already been proposed [78, 79].”
Self-citationBarrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Self-citation
Metadata
- Authors
- Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., Naumann, R., Spaepen, K., Hicks, R. J., Weber, W. A., Reske, S. N., Schwaiger, M., Schwartz, L. H., Zijlstra, J. M., Siegel, B. A., & Cheson, B. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-02-10
- Volume
- 25
- Issue
- 5
- Pages
- 571-578
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142724147
- Cited by
- 1,335
- References
- 29
- FWCI
- 76.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.